Gregory S. Hageman, PhD

Research Interests

  • The Biology, Genetics and Development of Diagnostic and Therapeutic Modalities for the Treatment of Age-Related Macular Degeneration and its Co-Segregating Diseases

Languages

  • English

Academic Information

  • Departments: Ophthalmology/Visual Sciences - Professor

Academic Office Information

  • John A. Moran Eye Center
    Opthalmology-Services
    65 N Mario Capecchi
    Salt Lake City, UT 84132

Academic Bio

Gregory Hageman is the John A. Moran Presidential Endowed Chair and the Executive Director of the Moran Eye Center for Translational Medicine at the University of Utah Moran Eye Center. He is an active member of professional and honorary organizations, and has served on numerous national and international advisory boards, service panels, and review committees. He has also been an advisor to numerous pharmaceutical and diagnostic companies.


Dr. Hageman’s primary research interest for over 20 years has been directed toward assessment of pathways involved in the etiology of age-related macular degeneration (AMD). Dr. Hageman and his colleagues discovered that AMD is characterized by robust activation of the complement cascade in the ocular macula and that variations in complement genes, including Complement Factor H (CFH), account for greater than 50% of risk for AMD in Caucasians. More recent discoveries relate to the role of the choriocapillaris in severe forms of AMD and diseases that co-segregate with it. Dr. Hageman has twice briefed the US Congress on his research findings and has received numerous awards for his contributions to AMD research. A major goal of Dr. Hageman’s current efforts is to expedite the pace at which basic scientific discoveries are translated into clinically effective therapies for the treatment of AMD and its co-segregating diseases.
Greg and his wife, Jill, have been married 33 years. They have two wonderful children, Nicholas and Courtney.

Education History

Type School Degree
Doctoral Training University of Southern California
Biology
Ph.D.
Undergraduate University of Southern California
Biological Sciences
B.S.

Selected Publications

Journal Article

  1. Gorusupudi A, Liu A, Hageman GS, Bernstein PS (2016). Associations of human retinal very long-chain polyunsaturated fatty acids with dietary lipid biomarkers. J Lipid Res, 57(3), 499-508.
  2. Keenan TD, Toso M, Pappas C, Nichols L, Bishop PN, Hageman GS (2015). Assessment of Proteins Associated With Complement Activation and Inflammation in Maculae of Human Donors Homozygous Risk at Chromosome 1 CFH-to-F13B. Invest Ophthalmol Vis Sci, 56(8), 4870-9.
  3. Wu Z, Luu CD, Ayton LN, Goh JK, Lucci LM, Hubbard WC, Hageman JL, Hageman GS, Guymer RH (2015). Fundus autofluorescence characteristics of nascent geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci, 56(3), 1546-52.
  4. Wu Z, Luu CD, Ayton LN, Goh JK, Lucci LM, Hubbard WC, Hageman JL, Hageman GS, Guymer RH (2014). Optical coherence tomography-defined changes preceding the development of drusen-associated atrophy in age-related macular degeneration. Ophthalmology, 121(12), 2415-22.
  5. Finger RP, Wu Z, Luu CD, Kearney F, Ayton LN, Lucci LM, Hubbard WC, Hageman JL, Hageman GS, Guymer RH (2014). Reticular pseudodrusen: a risk factor for geographic atrophy in fellow eyes of individuals with unilateral choroidal neovascularization. Ophthalmology, 121(6), 1252-6.

Patent

  1. Hageman GS, Smith RJ (2011). Methods and Reagents for Treatment and Diagnosis of Age-Related Macular Degeneration (CFH). U.S. Patent No. US 7867727 B2. Washington, D.C.:U.S. Patent and Trademark Office.
  2. Hageman GS (2010). Assessing Susceptibility to Vascular Disorders (ParAllele). U.S. Patent No. US20100324154 A1. Washington, D.C.:U.S. Patent and Trademark Office.
  3. Hageman GS (2010). Methods for Treatment of Age-related Macular Degeneration. U.S. Patent No. US 7745389 B2. Washington, D.C.:U.S. Patent and Trademark Office.
  4. Hageman GS, Mullins RF (2010). Diagnostics and Therapeutics for Macular Degeneration-Related Disorders. U.S. Patent No. US7682804 B2. Washington, D.C.:U.S. Patent and Trademark Office.
  5. Hageman GS (2010). RCA Locus Analysis to Assess Susceptibility to AMD and MPGNII. U.S. Patent No. WO2009059321 A3. Washington, D.C.:U.S. Patent and Trademark Office.
  6. Hageman GS (2009). Genes and Polymorphisms Associated with AMD (ParAllele). U.S. Patent No. WO/2009/059318. Washington, D.C.:U.S. Patent and Trademark Office.
  7. Hageman GS (2009). Predicting AMD with SNPs Within or Near C2, Factor B, PLEKHA1, HTRA1, PRELP, or LOC387715 (ParAllele). U.S. Patent No. WO2009059317 A3. Washington, D.C.:U.S. Patent and Trademark Office.
  8. Hageman GS, Mullins RF (2009). Diagnostics and Therapeutics for Drusen Associated Ocular Disorders (Drusen-associated Markers). U.S. Patent No. CA2363503. Washington, D.C.:U.S. Patent and Trademark Office.
  9. Hageman GS, Meri S (2008). Binding of Complement Factor H to C-Reactive Protein (CFH-CRP Binding). U.S. Patent No. EP2008101 A2. Washington, D.C.:U.S. Patent and Trademark Office.
  10. Allikmets RL, Hageman GS, Dean MC, Gold AM (2008). Variants In Complement Regulatory Genes Predict Age-Related Macular Degeneration (CFB/C2 Diagnostics). U.S. Patent No. WO2007120975 A8. Washington, D.C.:U.S. Patent and Trademark Office.
  11. Hageman GS (2008). Methods and Reagents for Treatment and Diagnosis of Vascular Disorders and Age-Related Macular Degeneration (CFHR1/R3 Deletion). U.S. Patent No. WO2008008986 A2. Washington, D.C.:U.S. Patent and Trademark Office.
  12. Hageman GS, Kuehn MH (2007). Nuclei Acids Encoding Interphotoreceptor Matrix Proteins (IPM). U.S. Patent No. US7312050. Washington, D.C.:U.S. Patent and Trademark Office.
  13. Hageman GS (2007). Biomarkers Associated With Age-Related Macular Degeneration (DIGE & MALDI Biomarkers). U.S. Patent No. WO2007032876 A2. Washington, D.C.:U.S. Patent and Trademark Office.
  14. Hageman, GS (2006). Diagnostics and Therapeutics for Macular Degeneration (AAA to AMD; EDP/CRP/C3/C5). U.S. Patent No. US7108982. Washington, D.C.:U.S. Patent and Trademark Office.
  15. Hageman GS, Mullins RF (2006). Diagnostics and Therapeutics for Macular Degeneration-Related Disorders (Autoantibodies). U.S. Patent No. US7011952. Washington, D.C.:U.S. Patent and Trademark Office.
  16. Hageman GS (2001). Diagnostics and Therapeutics for Arterial Wall Disruptive Disorders (AMD to AAA). U.S. Patent No. WO2001002866 A1. Washington, D.C.:U.S. Patent and Trademark Office.
  17. Neitz J, Anderson DH, Johnson LJ, Hageman GS (1995). Camouflage Materials for Reducing Visual Detection by Deer and Other Dichromatic Animals. U.S. Patent No. US5292509. Washington, D.C.:U.S. Patent and Trademark Office.
  18. Hageman GS (1994). Method for the Disinsertion of Vitreous Body by an Enzyme which Disrupts or Degrades Chondroitin Sulfate Proteoglycan. U.S. Patent No. US5741692. Washington, D.C.:U.S. Patent and Trademark Office.